iNNOVATE results: a prospective new standard of care for Waldenstrms macroglobulinemia
The purpose of the iNNOVATE study (NCT02165397) was to evaluate the safety and efficacy of ibrutinib and rituximab for the treatment of Waldenstrms macroglobulinemia (WM). Here, at the 23rd congress...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Venetoclax and rituximab: changing the treatment landscape in R/R CLL
Barbara Eichhorst, MD, from Uniklink Koln, Koln, Germany, talks to us about exciting new data for the venetoclax and rituximab combination in the MURANO Phase III trial (NCT02005471) for relapsed/refr...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Obinutuzumab increases survival in CLL patients with comorbidities
The CLL11 trial (NCT01998880) compared chlorambucil monotherapy with combination therapies of chlorambucil and anti-CD20 antibodies rituximab or obinutuzumab for chronic lymphocytic leukemia (CLL) in ...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
MURANO update: MRD, biological subsets & amp; safety analysis
MURANO (NCT02005471) is a Phase III randomized trial comparing the efficacy of venetoclax plus rituximab vs. standard chemoimmunotherapy of bendamustine plus rituximab in relapsed/refractory chronic l...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
MURANO update: MRD negativity in CLL
The MURANO trial (NCT02005471) compared the benefit of venetoclax plus rituximab vs. bendamustine plus rituximab in chronic lymphocytic leukemia (CLL), for which further results were presented at the ...
Author: VJHemOnc
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Ibrutinib & Rituximab is a new standard for WM Design trials that use the combination as a backbone
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Ibrutinib & Rituximab is a new standard for WM Design trials that use the combination as a backbone at ASCO 201...
Author: Annual-Meeting
Added: 06/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Venetoclax w Rituximab progressed the furthest Phase 3 Data shows the combination is superior
Matthew S. Davids, MD, MMSc, talks about how Venetoclax w Rituximab progressed the furthest Phase 3 Data shows the combination is superior Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Data Combining Venetoclax with Rituximab Half of patients achieved complete remission
Matthew S. Davids, MD, MMSc, Data Combining Venetoclax with Rituximab Half of patients achieved complete remission at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Rituximab vs. standard chemotherapy: which treatment benefits B-cell ALL patients more?
Can patients with B-cell acute lymphocytic leukemia (ALL) benefit more from using rituximab as part of their treatment compared to using standard chemotherapy alone? This is one question that Prof. Da...
Author: VJHemOnc
Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Rituximab Maintenance for Follicular Lymphoma CAR-T Trial salvages Primary, Refractory, or those who failed initial therapy
Elizabeth Brm, MD - HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Rituximab Maintenance for Follicular Lymphoma CAR-T Trial salvages Primary, Refractory, or those who fai...
Author: moasc
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Update on PRIMA Study Progression Free Survival from patients with Rituximab Maintenance
Elizabeth Brm, MD - HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses updates on PRIMA Study Progression Free Survival from patients with Rituximab Maintenance at MOASCs Spo...
Author: moasc
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Retrospective Analysis Looked At Rituximab Maintenance Patients achieving partial remission benefited most from rituximab maintenance
Elizabeth Brm, MD - HS Clinical Assistant Professor Chao Comprehensive Cancer Center<br />discusses updates Retrospective Analysis Looked At Rituximab Maintenance Patients achieving partial remission be...
Author: moasc
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Impacts of the MURANO study for future CLL treatment
Data from the Phase III MURANO study (NCT02005471) is a hot topic in the field of hematological oncology. The study evaluated the use of venetoclax plus rituximab vs. standard chemoimmunotherapy (bend...
Author: VJHemOnc
Added: 02/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 5, 2018 Category: Cancer & Oncology Source Type: podcasts
Bendamustine plus rituximab vs. standard therapy for advanced CLL
Fludarabine, cyclophosphamide and rituximab (FCR) is the standard chemotherapy regimen used to treat chronic lymphocytic leukaemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Ho...
Author: VJHemOnc
Added: 02/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 5, 2018 Category: Cancer & Oncology Source Type: podcasts
The adoption of biosimilars in Oxford: a case study
Identifying the optimal means of introducing biosimilars is an issue facing all clinics. Biosimilar rituximab was introduced in Oxford, UK in August 2017. Here, Nicola Stoner, BSc, PhD, MRPharmS, SPre...
Author: VJHemOnc
Added: 01/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 18, 2018 Category: Cancer & Oncology Source Type: podcasts
